Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
What was studied Across 37 studies (63 treatment arms, 9,341 adults) with overweight or obesity, the authors quantified how fast #weight returns after #discontinuing #medication, and compared this with regain after behavioural weight-management programmes (#BWMPs)
Opportunity Pathways - GLP-1 Diabetes Treatment Drugs Market The GLP-1 diabetes treatment drugs market represents one of the most explosive pharmaceutical opportunities of the decade, with the market projected to surge from USD 6,556.5 million in 2025 to USD 62,543.2 million by 2035 at an extraordinary 25.3% CAGRa 9.5X expansion driven by the global diabetes epidemic, breakthrough efficacy data, and expanding therapeutic applications beyond glucose control to include weight management and cardiovascular protection
99% purity by HPLC
About ATTAIN-1 and ATTAIN-2 clinical trial program The ATTAIN Phase III global clinical development program for orforglipron has enrolled more than 4,500 people with obesity or overweight across two global registration trials
Again though, the effects in this regard are likely to be moderate or even clinically insignificant
)
